Today’s S&P 500 Highlights: Oracle and Nvidia Surge While Kenvue Takes a Dive

On September 22, 2025, shares of Teradyne, a semiconductor testing firm, shot up 13%. An analyst raised Teradyne’s price target, noting a strong demand for its automated test equipment. This company is collaborating more with Taiwan Semiconductor Manufacturing Company, a key player in the chip industry, which is driving positive expectations for future growth.

Meanwhile, consumer health company Kenvue saw its shares tumble by 7.5%. Reports circulated that the Trump administration might link Tylenol, a drug produced by Kenvue, to increased autism risk. Kenvue has firmly stated that scientific studies do not support any such link. This news generated buzz online, with many users expressing their concerns about safety and government transparency.

The stock market overall had a positive day. Major indices closed higher. The S&P 500 rose 0.4%, marking its third straight day of record highs. Nvidia announced plans to invest up to $100 million in OpenAI, which fueled excitement around artificial intelligence, contributing to an increase of 4% in Nvidia’s stock.

Oracle’s shares also climbed by 6.3% after it was confirmed that the company will oversee TikTok’s U.S. operations. This move is part of a consortium aimed at ensuring data privacy and security as tensions around tech and national security continue to rise.

Moderna’s stock increased by 5.2% after the CDC clarified its COVID-19 vaccination guidelines. The updated advice suggests people should discuss vaccination with their doctors instead of mandating a shot for everyone.

Westinghouse Air Brake Technologies, known as Wabtec, announced a $4 billion deal to supply locomotives to Kazakhstan, pushing its shares up by 4.9%. Analysts anticipate that Wabtec will benefit from increasing infrastructure investments.

In contrast, Lennar, a major homebuilder, reported disappointing quarterly results and saw shares drop by 4.3%. Analysts expressed concerns about the company’s profit margins and its reliance on incentives to attract buyers.

The reactions on social media vary widely, especially regarding Kenvue. Users are taking to platforms like Twitter to share experiences and insights about Tylenol’s safety, highlighting the power of social media in shaping public perception.

As we navigate the complexities of the market and public health discussions, it’s crucial to stay informed and engage in conversations. Resources like the CDC and financial news outlets provide valuable information on these evolving situations.

Source link